Synergistic Effect of Formate and Cell-Free Supernatant Fermented by Two Probiotics, Bifidobacterium animalis spp. lactis HN019 and Lacticaseibacillus rhamnosus HN001, against Shigella flexneri Growth
- PMID: 40371449
- DOI: 10.1021/acsinfecdis.4c00796
Synergistic Effect of Formate and Cell-Free Supernatant Fermented by Two Probiotics, Bifidobacterium animalis spp. lactis HN019 and Lacticaseibacillus rhamnosus HN001, against Shigella flexneri Growth
Abstract
The interplay between probiotic metabolites, host health, and inhibition of pathogens has increasingly attracted interest but remains unresolved due to the complex molecular interactions among these factors. We investigated the action of cell-free supernatants (CFSs) from two probiotic bacteria, Bifidobacterium animalis spp. lactis (B. lactis) HN019 and Lacticaseibacillus rhamnosus (L. rhamnosus) HN001 and their effect against the bacterial pathogen Shigella flexneri 2457T (S. flexneri). The CFSs from B. lactis HN019 exhibited a higher antibacterial effect against S. flexneri growth than the CFSs from L. rhamnosus HN001, independent of the carbon source utilized. This effect correlated with higher formate within the CFSs from B. lactis HN019. As expected, the antimicrobial effects of CFSs were stronger against free S. flexneri cells than for S. flexneri infecting host cells. A synergistic effect of the CFSs with additional small organic molecules such as indole-3-lactate and formate was found. Such interplay between CFSs, indole-3-lactate, and formate was reflected by altered metabolic rates by S. flexneri in the presence of B. lactis HN019 CFSs both in the solution and under biofilm-forming conditions. The synergistic effect between different components acting on S. flexneri gives reasons to believe that suitably designed mixtures of probiotic metabolic products and small-molecule effectors bear promise for successfully combating pathogens.
Keywords: Shigella flexneri; antibacterial mechanism; cell-free supernatants; lactic acid bacteria; metabolism.
Similar articles
-
Comparison of two probiotics in follow-on formula: Bifidobacterium animalis subsp. lactis HN019 reduced upper respiratory tract infections in Chinese infants.Benef Microbes. 2022 Oct 4;13(4):341-354. doi: 10.3920/BM2022.0041. Epub 2022 Aug 25. Benef Microbes. 2022. PMID: 36004715 Clinical Trial.
-
In Vitro and In Vivo Evaluation of Lacticaseibacillus rhamnosus GG and Bifidobacterium lactis Bb12 Against Avian Pathogenic Escherichia coli and Identification of Novel Probiotic-Derived Bioactive Peptides.Probiotics Antimicrob Proteins. 2022 Dec;14(6):1012-1028. doi: 10.1007/s12602-021-09840-1. Epub 2021 Aug 30. Probiotics Antimicrob Proteins. 2022. PMID: 34458959
-
Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization?Clin Exp Allergy. 2013 Sep;43(9):1048-57. doi: 10.1111/cea.12154. Clin Exp Allergy. 2013. PMID: 23957340
-
Use of the Probiotic Bifidobacterium animalis subsp. lactis HN019 in Oral Diseases.Int J Mol Sci. 2022 Aug 19;23(16):9334. doi: 10.3390/ijms23169334. Int J Mol Sci. 2022. PMID: 36012597 Free PMC article. Review.
-
Health benefits of Lactobacillus rhamnosus GG and Bifidobacterium animalis subspecies lactis BB-12 in children.Postgrad Med. 2020 Jun;132(5):441-451. doi: 10.1080/00325481.2020.1731214. Epub 2020 Feb 26. Postgrad Med. 2020. PMID: 32059116 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous